img

Global Anaplastic Lymphoma Kinase Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Anaplastic Lymphoma Kinase Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[
Anaplastic Lymphoma Kinase Inhibitors report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anaplastic Lymphoma Kinase Inhibitors market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from NSCLC and Breast Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anaplastic Lymphoma Kinase Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Anaplastic Lymphoma Kinase Inhibitors key manufacturers include Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd. and Xcovery Holding Company, LLC, etc. Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd. are top 3 players and held % sales share in total in 2022.
Anaplastic Lymphoma Kinase Inhibitors can be divided into Crizotinib, Ceritinib and Alectinib Hydrochloride,, etc. Crizotinib is the mainstream product in the market, accounting for % sales share globally in 2022.
Anaplastic Lymphoma Kinase Inhibitors is widely used in various fields, such as NSCLC, Breast Cancer, Colorectal Cancer and Neuroblastoma, etc. NSCLC provides greatest supports to the Anaplastic Lymphoma Kinase Inhibitors industry development. In 2022, global % sales of Anaplastic Lymphoma Kinase Inhibitors went into NSCLC filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anaplastic Lymphoma Kinase Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Betta Pharmaceutcials Co., Ltd.
Crtierium, Inc.
F.Hoffman-La Roche Ltd.
Helsinn Therapeutics
Novartis AG.
Oncoethix GmbH
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
Xcovery Holding Company, LLC
Tesaro, Inc.
Segment by Type
Crizotinib
Ceritinib
Alectinib Hydrochloride

Segment by Application


NSCLC
Breast Cancer
Colorectal Cancer
Neuroblastoma
Ovarian Cancer
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Anaplastic Lymphoma Kinase Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anaplastic Lymphoma Kinase Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anaplastic Lymphoma Kinase Inhibitors industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Anaplastic Lymphoma Kinase Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anaplastic Lymphoma Kinase Inhibitors introduction, etc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Anaplastic Lymphoma Kinase Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Anaplastic Lymphoma Kinase Inhibitors Market Overview
1.1 Anaplastic Lymphoma Kinase Inhibitors Product Overview
1.2 Anaplastic Lymphoma Kinase Inhibitors Market Segment by Type
1.2.1 Crizotinib
1.2.2 Ceritinib
1.2.3 Alectinib Hydrochloride
1.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Type
1.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Overview by Type (2024-2034)
1.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Historic Market Size Review by Type (2024-2024)
1.3.3 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Type (2024-2024)
1.4.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Type (2024-2024)
2 Global Anaplastic Lymphoma Kinase Inhibitors Market Competition by Company
2.1 Global Top Players by Anaplastic Lymphoma Kinase Inhibitors Sales (2024-2024)
2.2 Global Top Players by Anaplastic Lymphoma Kinase Inhibitors Revenue (2024-2024)
2.3 Global Top Players by Anaplastic Lymphoma Kinase Inhibitors Price (2024-2024)
2.4 Global Top Manufacturers Anaplastic Lymphoma Kinase Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Anaplastic Lymphoma Kinase Inhibitors Market Competitive Situation and Trends
2.5.1 Anaplastic Lymphoma Kinase Inhibitors Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Anaplastic Lymphoma Kinase Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Anaplastic Lymphoma Kinase Inhibitors Market
2.8 Key Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Anaplastic Lymphoma Kinase Inhibitors Status and Outlook by Region
3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Region
3.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2024-2024)
3.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2024-2024)
3.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Region
3.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2024-2034)
3.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2024-2034)
3.3.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Anaplastic Lymphoma Kinase Inhibitors by Application
4.1 Anaplastic Lymphoma Kinase Inhibitors Market Segment by Application
4.1.1 NSCLC
4.1.2 Breast Cancer
4.1.3 Colorectal Cancer
4.1.4 Neuroblastoma
4.1.5 Ovarian Cancer
4.1.6 Others
4.2 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Application
4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Overview by Application (2024-2034)
4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Historic Market Size Review by Application (2024-2024)
4.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Application (2024-2024)
4.3.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Breakdown by Application (2024-2024)
5 North America Anaplastic Lymphoma Kinase Inhibitors by Country
5.1 North America Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Country
5.1.1 North America Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2024)
5.1.3 North America Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2024)
5.2 North America Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Country
5.2.1 North America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2034)
5.2.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2034)
6 Europe Anaplastic Lymphoma Kinase Inhibitors by Country
6.1 Europe Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Country
6.1.1 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2024)
6.1.3 Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2024)
6.2 Europe Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Country
6.2.1 Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2034)
6.2.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2034)
7 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors by Region
7.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Region (2024-2034)
8 Latin America Anaplastic Lymphoma Kinase Inhibitors by Country
8.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Country
8.1.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2024)
8.1.3 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2024)
8.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2034)
8.2.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2034)
9 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors by Country
9.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Betta Pharmaceutcials Co., Ltd.
10.1.1 Betta Pharmaceutcials Co., Ltd. Company Information
10.1.2 Betta Pharmaceutcials Co., Ltd. Introduction and Business Overview
10.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.1.5 Betta Pharmaceutcials Co., Ltd. Recent Development
10.2 Crtierium, Inc.
10.2.1 Crtierium, Inc. Company Information
10.2.2 Crtierium, Inc. Introduction and Business Overview
10.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.2.5 Crtierium, Inc. Recent Development
10.3 F.Hoffman-La Roche Ltd.
10.3.1 F.Hoffman-La Roche Ltd. Company Information
10.3.2 F.Hoffman-La Roche Ltd. Introduction and Business Overview
10.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.3.5 F.Hoffman-La Roche Ltd. Recent Development
10.4 Helsinn Therapeutics
10.4.1 Helsinn Therapeutics Company Information
10.4.2 Helsinn Therapeutics Introduction and Business Overview
10.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.4.5 Helsinn Therapeutics Recent Development
10.5 Novartis AG.
10.5.1 Novartis AG. Company Information
10.5.2 Novartis AG. Introduction and Business Overview
10.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.5.5 Novartis AG. Recent Development
10.6 Oncoethix GmbH
10.6.1 Oncoethix GmbH Company Information
10.6.2 Oncoethix GmbH Introduction and Business Overview
10.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.6.5 Oncoethix GmbH Recent Development
10.7 Pfizer, Inc.
10.7.1 Pfizer, Inc. Company Information
10.7.2 Pfizer, Inc. Introduction and Business Overview
10.7.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.7.5 Pfizer, Inc. Recent Development
10.8 Takeda Pharmaceutical Co., Ltd.
10.8.1 Takeda Pharmaceutical Co., Ltd. Company Information
10.8.2 Takeda Pharmaceutical Co., Ltd. Introduction and Business Overview
10.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.8.5 Takeda Pharmaceutical Co., Ltd. Recent Development
10.9 Xcovery Holding Company, LLC
10.9.1 Xcovery Holding Company, LLC Company Information
10.9.2 Xcovery Holding Company, LLC Introduction and Business Overview
10.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.9.5 Xcovery Holding Company, LLC Recent Development
10.10 Tesaro, Inc.
10.10.1 Tesaro, Inc. Company Information
10.10.2 Tesaro, Inc. Introduction and Business Overview
10.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Products Offered
10.10.5 Tesaro, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Anaplastic Lymphoma Kinase Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Anaplastic Lymphoma Kinase Inhibitors Industrial Chain Analysis
11.4 Anaplastic Lymphoma Kinase Inhibitors Market Dynamics
11.4.1 Anaplastic Lymphoma Kinase Inhibitors Industry Trends
11.4.2 Anaplastic Lymphoma Kinase Inhibitors Market Drivers
11.4.3 Anaplastic Lymphoma Kinase Inhibitors Market Challenges
11.4.4 Anaplastic Lymphoma Kinase Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Anaplastic Lymphoma Kinase Inhibitors Distributors
12.3 Anaplastic Lymphoma Kinase Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Crizotinib
Table 2. Major Company of Ceritinib
Table 3. Major Company of Alectinib Hydrochloride
Table 4. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 5. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (MT)
Table 6. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type (2024-2024)
Table 7. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US& Million)
Table 8. Global Anaplastic Lymphoma Kinase Inhibitors Market Share in Value by Type (2024-2024)
Table 9. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2024-2024) & (USD/MT)
Table 10. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2034) & (MT)
Table 11. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type (2024-2034)
Table 14. Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2024-2034) & (USD/MT)
Table 15. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (MT)
Table 16. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 17. Europe Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2024-2024)
Table 18. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 19. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2024-2024)
Table 20. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 21. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2024-2024)
Table 22. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 23. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2024-2024)
Table 24. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 25. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Company (2024-2024) & (MT)
Table 26. Global Anaplastic Lymphoma Kinase Inhibitors Sales Share by Company (2024-2024)
Table 27. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Company (2024-2024) & (US$ Million)
Table 28. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Company (2024-2024)
Table 29. Global Market Anaplastic Lymphoma Kinase Inhibitors Price by Company (2024-2024) & (USD/MT)
Table 30. Global Anaplastic Lymphoma Kinase Inhibitors Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Anaplastic Lymphoma Kinase Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2022)
Table 33. Date of Key Manufacturers Enter into Anaplastic Lymphoma Kinase Inhibitors Market
Table 34. Key Manufacturers Anaplastic Lymphoma Kinase Inhibitors Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Anaplastic Lymphoma Kinase Inhibitors Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 37. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2024) & (MT)
Table 38. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 39. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 40. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 41. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2024-2024)
Table 42. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2034) & (MT)
Table 43. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 46. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2024-2034)
Table 47. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 48. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (MT)
Table 49. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application (2024-2024)
Table 50. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 51. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application (2024-2024)
Table 52. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2024-2024) & (USD/MT)
Table 53. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2034) & (MT)
Table 54. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application (2024-2034)
Table 57. Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2024-2034) & (USD/MT)
Table 58. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) (MT)
Table 59. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 60. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) (MT)
Table 61. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 62. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) (MT)
Table 63. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 64. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) (MT)
Table 65. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 66. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) (MT)
Table 67. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 68. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (MT)
Table 69. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 70. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 71. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 72. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (MT)
Table 73. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (MT)
Table 77. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 78. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 79. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 80. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (MT)
Table 81. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2024) & (MT)
Table 85. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 86. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 87. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 88. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2034) & (MT)
Table 89. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (MT)
Table 93. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 94. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 95. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 96. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (MT)
Table 97. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (MT)
Table 101. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 102. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 103. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 104. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (MT)
Table 105. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 108. Betta Pharmaceutcials Co., Ltd. Company Information
Table 109. Betta Pharmaceutcials Co., Ltd. Introduction and Business Overview
Table 110. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 111. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 112. Betta Pharmaceutcials Co., Ltd. Recent Development
Table 113. Crtierium, Inc. Company Information
Table 114. Crtierium, Inc. Introduction and Business Overview
Table 115. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 116. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table 117. Crtierium, Inc. Recent Development
Table 118. F.Hoffman-La Roche Ltd. Company Information
Table 119. F.Hoffman-La Roche Ltd. Introduction and Business Overview
Table 120. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 121. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 122. F.Hoffman-La Roche Ltd. Recent Development
Table 123. Helsinn Therapeutics Company Information
Table 124. Helsinn Therapeutics Introduction and Business Overview
Table 125. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 126. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product
Table 127. Helsinn Therapeutics Recent Development
Table 128. Novartis AG. Company Information
Table 129. Novartis AG. Introduction and Business Overview
Table 130. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 131. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product
Table 132. Novartis AG. Recent Development
Table 133. Oncoethix GmbH Company Information
Table 134. Oncoethix GmbH Introduction and Business Overview
Table 135. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 136. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product
Table 137. Oncoethix GmbH Recent Development
Table 138. Pfizer, Inc. Company Information
Table 139. Pfizer, Inc. Introduction and Business Overview
Table 140. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 141. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table 142. Pfizer, Inc. Recent Development
Table 143. Takeda Pharmaceutical Co., Ltd. Company Information
Table 144. Takeda Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 145. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 146. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product
Table 147. Takeda Pharmaceutical Co., Ltd. Recent Development
Table 148. Xcovery Holding Company, LLC Company Information
Table 149. Xcovery Holding Company, LLC Introduction and Business Overview
Table 150. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 151. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product
Table 152. Xcovery Holding Company, LLC Recent Development
Table 153. Tesaro, Inc. Company Information
Table 154. Tesaro, Inc. Introduction and Business Overview
Table 155. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2024-2024)
Table 156. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product
Table 157. Tesaro, Inc. Recent Development
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. Anaplastic Lymphoma Kinase Inhibitors Market Trends
Table 161. Anaplastic Lymphoma Kinase Inhibitors Market Drivers
Table 162. Anaplastic Lymphoma Kinase Inhibitors Market Challenges
Table 163. Anaplastic Lymphoma Kinase Inhibitors Market Restraints
Table 164. Anaplastic Lymphoma Kinase Inhibitors Distributors List
Table 165. Anaplastic Lymphoma Kinase Inhibitors Downstream Customers
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Anaplastic Lymphoma Kinase Inhibitors Product Picture
Figure 2. Global Anaplastic Lymphoma Kinase Inhibitors Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Anaplastic Lymphoma Kinase Inhibitors Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Anaplastic Lymphoma Kinase Inhibitors Sales Status and Outlook (2024-2034) & (MT)
Figure 5. Product Picture of Crizotinib
Figure 6. Global Crizotinib Sales YoY Growth (2024-2034) & (MT)
Figure 7. Product Picture of Ceritinib
Figure 8. Global Ceritinib Sales YoY Growth (2024-2034) & (MT)
Figure 9. Product Picture of Alectinib Hydrochloride
Figure 10. Global Alectinib Hydrochloride Sales YoY Growth (2024-2034) & (MT)
Figure 11. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2024-2034) & (US$ Million)
Figure 12. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type in 2022 & 2034
Figure 13. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type in 2022
Figure 14. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type in 2022
Figure 15. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type in 2022
Figure 16. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type in 2022
Figure 19. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Anaplastic Lymphoma Kinase Inhibitors Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Anaplastic Lymphoma Kinase Inhibitors Revenue in 2022
Figure 25. Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 26. Product Picture of NSCLC
Figure 27. Global NSCLC Sales YoY Growth (2024-2034) & (MT)
Figure 28. Product Picture of Breast Cancer
Figure 29. Global Breast Cancer Sales YoY Growth (2024-2034) & (MT)
Figure 30. Product Picture of Colorectal Cancer
Figure 31. Global Colorectal Cancer Sales YoY Growth (2024-2034) & (MT)
Figure 32. Product Picture of Neuroblastoma
Figure 33. Global Neuroblastoma Sales YoY Growth (2024-2034) & (MT)
Figure 34. Product Picture of Ovarian Cancer
Figure 35. Global Ovarian Cancer Sales YoY Growth (2024-2034) & (MT)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2024-2034) & (MT)
Figure 38. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2024-2034) & (US$ Million)
Figure 39. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application in 2022 & 2034
Figure 40. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application in 2022
Figure 41. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application in 2022
Figure 42. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application in 2022
Figure 43. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application in 2022
Figure 46. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Anaplastic Lymphoma Kinase Inhibitors Manufacturing Cost Structure
Figure 51. Anaplastic Lymphoma Kinase Inhibitors Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries